Compare OSPN & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSPN | RIGL |
|---|---|---|
| Founded | 1991 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 946.7M | 911.8M |
| IPO Year | 2000 | 2000 |
| Metric | OSPN | RIGL |
|---|---|---|
| Price | $22.15 | $39.76 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $23.50 | ★ $64.40 |
| AVG Volume (30 Days) | ★ 897.0K | 204.0K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | 28.77 | ★ 1867.68 |
| EPS | 0.68 | ★ 1.97 |
| Revenue | $243,180,000.00 | ★ $294,282,000.00 |
| Revenue This Year | $5.28 | $5.32 |
| Revenue Next Year | $2.44 | $24.14 |
| P/E Ratio | $33.19 | ★ $21.00 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $10.07 | $24.84 |
| 52 Week High | $27.45 | $52.61 |
| Indicator | OSPN | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 53.32 | 34.58 |
| Support Level | $21.29 | $37.60 |
| Resistance Level | $27.45 | $43.74 |
| Average True Range (ATR) | 1.13 | 2.72 |
| MACD | -0.20 | -0.62 |
| Stochastic Oscillator | 16.78 | 15.98 |
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. The company build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity solutions engaged in protecting identities, securing mobile apps, and safeguarding access through high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks, while Digital agreement solutions focuses on streamlining workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance and other customer experiences.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.